⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity

Every month we try and update this database with for stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Biomarkers in Patients With Head and Neck CancerNCT01466257
Head and Neck C...
cetuximab
cisplatin
DNA analysis
gene expression...
mutation analys...
laboratory biom...
18 Years - 120 YearsEastern Cooperative Oncology Group
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00096512
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
sorafenib tosyl...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02035527
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Oral ...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
sorafenib tosyl...
cisplatin
docetaxel
Correlative Stu...
18 Years - Ohio State University Comprehensive Cancer Center
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation TherapyNCT01728480
Mucositis
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
entolimod
intensity-modul...
cisplatin
pharmacological...
laboratory biom...
18 Years - Roswell Park Cancer Institute
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerNCT00114283
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
lapatinib ditos...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNCT00939627
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
cetuximab
placebo
sorafenib tosyl...
laboratory biom...
quality-of-life...
18 Years - National Cancer Institute (NCI)
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerNCT02245100
Metastatic Squa...
Salivary Gland ...
Stage IIIA Non-...
Stage IIIB Non-...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
Cytology specim...
Laboratory biom...
18 Years - Thomas Jefferson University
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation TherapyNCT01728480
Mucositis
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
entolimod
intensity-modul...
cisplatin
pharmacological...
laboratory biom...
18 Years - Roswell Park Cancer Institute
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckNCT00033618
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
ixabepilone
laboratory biom...
18 Years - National Cancer Institute (NCI)
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397NCT01466244
Head and Neck C...
cetuximab
cisplatin
gene expression...
microarray anal...
immunohistochem...
laboratory biom...
18 Years - 120 YearsEastern Cooperative Oncology Group
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00095628
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Saliv...
Stage IVC Squam...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckNCT01334177
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Saliva...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
TLR8 agonist VT...
cetuximab
laboratory biom...
pharmacogenomic...
18 Years - University of Washington
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397NCT01466244
Head and Neck C...
cetuximab
cisplatin
gene expression...
microarray anal...
immunohistochem...
laboratory biom...
18 Years - 120 YearsEastern Cooperative Oncology Group
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT00103259
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Tongue Cancer
bortezomib
irinotecan hydr...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNCT00939627
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
cetuximab
placebo
sorafenib tosyl...
laboratory biom...
quality-of-life...
18 Years - National Cancer Institute (NCI)
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00095628
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Saliv...
Stage IVC Squam...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerNCT01637194
Recurrent Adeno...
Recurrent Basal...
Recurrent Colon...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Adenoi...
Stage IV Basal ...
Stage IV Lympho...
Stage IV Lympho...
Stage IV Mucoep...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Colon...
Stage IVA Esthe...
Stage IVA Inver...
Stage IVA Midli...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Colon...
Stage IVB Esthe...
Stage IVB Inver...
Stage IVB Midli...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Esthe...
Stage IVC Inver...
Stage IVC Midli...
Stage IVC Saliv...
Stage IVC Squam...
Tongue Cancer
everolimus
cetuximab
pharmacological...
laboratory biom...
18 Years - Fox Chase Cancer Center
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT01816984
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
PI3K inhibitor ...
cetuximab
18 Years - University of Chicago
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: